Repairing gut saves brain function after stroke

Stroke is a leading cause of death, dementia and serious long-term disability. 

To improve stroke outcomes, scientists in the Texas A&M University School of Medicine in the United States are pioneering research into the connection between stroke-induced gut permeability, or leakiness, and cognitive impairment.

The Texas A&M team investigated the novel idea whether transplant of intestinal epithelial stem cells (IESCs) from healthy donors could repair the intestinal barrier after stroke and improve stroke outcomes.

Results from their preclinical study, published in the journal Brain, Behavior, and Immunity, indicate that IESC transplantation reduced stroke-induced mortality, decreased the volume of dead tissue and gut leakiness, and prevented stroke-induced cognitive impairment.

Two-thirds of stroke patients will develop cognitive impairment, while one-third of all stroke patients will go on to develop dementia, according to recent research, so there is a critical need for more effective stroke therapies that preserve cognitive function after acute stroke and that remain protective in the weeks following.

Although conventional stroke treatment research focuses on the brain, the gut responds early and rapidly to stroke with changes that may precede many of the inflammatory events associated with stroke-induced disease.

These changes in the gut, such as increased permeability, likely result in the movement of products that are synthesized in the gut into the blood stream.

Many of these products are toxic and therefore in a position to increase inflammation and exacerbate stroke-induced brain injury.

Evidence from a variety of studies demonstrates that IESCs repair the gut and reduce gut permeability.

After a stroke, these repair processes may be critical to preserving cognitive function.

“It is clear that the gut-brain axis is involved in injury following stroke,” said Farida Sohrabji, PhD, Regents Professor, department head for Neuroscience and Experimental Therapeutics and senior author of the study (pictured).

“Factoring in the effects of gut health on the brain following stroke may allow us to more effectively advance stroke therapies.”

With that in mind, Sohrabji and her team transplanted primary IESCs from healthy donors after stroke in a preclinical model.

IESCs from young donors repaired gut architecture and decreased gut permeability and consequently decreasing blood levels of proteins and other molecules that are toxic to brain cells.

IESC transplantation also prevented depressive-like behaviours and cognitive impairment in the weeks following the stroke.

IESC transplantation from older donors did not improve stroke outcomes, indicating that successful transplantation depends on the age of the donor.

Still at the preclinical stage, this research highlights the importance of early therapeutic intervention after stroke and will guide future directions of the work.

“Future studies will investigate refinement of the dosing and timing of the protocol,” Sohrabji said.

“A systematic study of aging stem cells would also be important to explain why older patients experience more severe strokes.”

Sohrabji, a neuroscientist with significant contributions to the literature on stroke pathogenesis, explained that this preclinical study was spearheaded by Kathiresh Kumar Mani, PhD, an associate research scientist in her lab.

Mani, who is trained in gut biology, received a postdoctoral grant from the American Heart Association in support of this project.

Combining their expertise has allowed them to move stroke therapy research into new territory with exciting results.

They also received a generous grant from the WoodNext Foundation that is facilitating their innovative research.

“Ultimately, this research is expected to advance development of novel therapies that target and repair the intestinal epithelium to help mitigate stroke disability,” Sohrabji said, “but the premise—that gut stem cells might be therapeutically valuable outside of the gut—could be considered for a much greater variety of neurological diseases.”